Thetis Pharmaceuticals Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $560K

  • Investors
  • 9

Thetis Pharmaceuticals General Information

Description

Developer of oral therapeutics designed to treat inflammatory bowel diseases and solid tumors. The company's drug candidates target the Resolvin E1 signaling pathway to regulate immune responses, promote tissue repair, and reduce fibrosis, enabling healthcare providers to address chronic inflammation and treat patients with inflammatory bowel diseases and advanced cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12 Main Street
  • Suite 5
  • Essex, CT 06426
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 12 Main Street
  • Suite 5
  • Essex, CT 06426
  • United States
+1 (617)

Thetis Pharmaceuticals Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thetis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Later Stage VC 13-Oct-2026 $560K Completed Clinical Trials - Phase 1
15. Grant 02-Jun-2023 Completed Clinical Trials - Phase 1
14. Secondary Transaction - Private Completed Clinical Trials - Phase 1
13. Later Stage VC 11-Jul-2022 Completed Clinical Trials - Phase 1
12. Grant 05-Apr-2022 Completed Clinical Trials - Phase 1
11. Grant 06-Aug-2021 Completed Clinical Trials - Phase 1
10. Later Stage VC 02-Nov-2020 Completed Clinical Trials - Phase 1
9. Later Stage VC 31-Oct-2020 Completed Clinical Trials - Phase 1
8. Grant 01-Mar-2020 $1.98M $14.2M Completed Clinical Trials - Phase 1
7. Grant 30-Nov-2019 $2.3M $14.2M Completed Clinical Trials - Phase 1
To view Thetis Pharmaceuticals’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Thetis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oral therapeutics designed to treat inflammatory bowel diseases and solid tumors. The company's drug candid
Drug Discovery
Essex, CT
7 As of 2022

New York, NY
 

Newark, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Thetis Pharmaceuticals Competitors (4)

One of Thetis Pharmaceuticals’s 4 competitors is Immunic Therapeutics, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunic Therapeutics Formerly VC-backed New York, NY
Protagonist Therapeutics Formerly VC-backed Newark, CA
Athersys Formerly VC-backed Cleveland, OH
Xeris Biopharma Holdings Formerly VC-backed Chicago, IL
To view Thetis Pharmaceuticals’s complete competitors history, request access »

Thetis Pharmaceuticals Patents

Thetis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240180859-A1 Compositions and methods for immune-mediated inflammatory diseases Inactive 26-Oct-2022
AU-2023228890-A1 Cyclodextrin complexes of specialized proresolving mediators Pending 03-Mar-2022
EP-4486393-A2 Cyclodextrin complexes of specialized proresolving mediators Pending 03-Mar-2022
US-12564644-B2 Cyclodextrin complexes of specialized proresolving mediators Active 03-Mar-2022
US-20240408229-A1 Cyclodextrin complexes of specialized proresolving mediators Active 03-Mar-2022 A61K47/6951
To view Thetis Pharmaceuticals’s complete patent history, request access »

Thetis Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thetis Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
The Leona M. and Harry B. Helmsley Charitable Trust Limited Partner
Crohn's & Colitis Foundation Limited Partner
Kenneth Rainin Foundation Limited Partner
National Institute Of Allergy and Infectious Diseases Government
You’re viewing 5 of 9 investors. Get the full list »

Thetis Pharmaceuticals FAQs

  • When was Thetis Pharmaceuticals founded?

    Thetis Pharmaceuticals was founded in 2011.

  • Where is Thetis Pharmaceuticals headquartered?

    Thetis Pharmaceuticals is headquartered in Essex, CT.

  • What is the size of Thetis Pharmaceuticals?

    Thetis Pharmaceuticals has 7 total employees.

  • What industry is Thetis Pharmaceuticals in?

    Thetis Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Thetis Pharmaceuticals a private or public company?

    Thetis Pharmaceuticals is a Private company.

  • What is Thetis Pharmaceuticals’s current revenue?

    The current revenue for Thetis Pharmaceuticals is .

  • How much funding has Thetis Pharmaceuticals raised over time?

    Thetis Pharmaceuticals has raised $57.6M.

  • Who are Thetis Pharmaceuticals’s investors?

    , The Leona M. and Harry B. Helmsley Charitable Trust, Crohn's & Colitis Foundation, Kenneth Rainin Foundation, and National Institute Of Allergy and Infectious Diseases are 5 of 9 investors who have invested in Thetis Pharmaceuticals.

  • Who are Thetis Pharmaceuticals’s competitors?

    Immunic Therapeutics, Protagonist Therapeutics, Athersys, and Xeris Biopharma Holdings are competitors of Thetis Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process